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Protocol
AbstrACt
Introduction There is rising awareness that we need 
multidisciplinary approaches integrating psychological 
treatments for schizophrenia, but a comprehensive 
evidence based on their relative efficacy is lacking. We will 
conduct a network meta-analysis (NMA), integrating direct 
and indirect comparisons from randomised controlled trials 
(RCTs) to rank psychological treatments for schizophrenia 
according to their efficacy, acceptability and tolerability.
Methods and analysis We will include all RCTs 
comparing a psychological treatment aimed at positive 
symptoms of schizophrenia with another psychological 
intervention or with a no treatment condition (waiting-
list and treatment as usual). We will include studies on 
adult patients with schizophrenia, excluding specific 
subpopulations (eg, first-episode patients or patients 
with psychiatric comorbidities). Primary outcome will 
be the change in positive symptoms on a published 
rating scale. Secondary outcomes will be acceptability 
(dropout), change in overall and negative symptoms of 
schizophrenia, response, relapse, adherence, depression, 
quality of life, functioning and adverse events. Published 
and unpublished studies will be sought through database 
searches, trial registries and websites. Study selection 
and data extraction will be conducted by at least two 
independent reviewers. We will conduct random-effects 
NMA to synthesise all evidences for each outcome and 
obtain a comprehensive ranking of all treatments. NMA 
will be conducted in Stata and R within a frequentist 
framework. The risk of bias in studies will be evaluated 
using the Cochrane Risk of Bias tool and the credibility of 
the evidence will be evaluated using an adaptation of the 
Grading of Recommendations Assessment, Development 
and Evaluation framework to NMA, recommended by the 
Cochrane guidance. Subgroup and sensitivity analyses will 
be conducted to assess the robustness of the findings.
Ethics and dissemination No ethical issues are foreseen. 
Results from this study will be published in peer-reviewed 
journals and presented at relevant conferences. 
PrOsPErO registration number CRD42017067795.
IntrOduCtIOn 
Schizophrenia is a debilitating and often life-
long disorder that ranks among the top 20 
causes of disability according to the World 
Health Report.1 Although pharmacological 
interventions have been the mainstay of treat-
ment for schizophrenia, antipsychotics have 
a number of limitations (limited response, 
high incidence of disabling side effects and 
poor adherence to treatment)2 and are prob-
lematic in many situations (such as medical 
comorbidities, tolerability problems and 
pregnancy). Besides, there has been growing 
recognition of the importance of psycholog-
ical processes in psychosis, both as contribu-
tors to onset and persistence, and in terms of 
the negative psychological impact of a diag-
nosis of schizophrenia on the individual’s 
well-being, psychosocial functioning and life 
opportunities. Psychological interventions 
strengths and limitations of this study
 ► We will conduct a random-effects network meta-
analysis (NMA) to synthesise all available published 
or unpublished randomised controlled trials for each 
prespecified outcome and obtain a comprehensive 
ranking of all treatments.
 ► This will be the first NMA on psychological 
treatments for schizophrenia; the findings from this 
study have the potential to inform and influence 
clinical decision-making and guideline development.
 ► The risk of heterogeneity and inconsistency is high, 
given the different psychological interventions that 
will be included: however, we try to control variability 
by carefully framing the inclusion criteria about 
population and interventions, and we will evaluate 
consistency employing local as well as global 
methods.
 ► The limitations of primary studies will be addressed 
with the Cochrane risk of bias tool, and the quality 
of evidence for network estimates will be assessed 
with an appropriate adaptation of the Grading of 
Recommendations Assessment, Development 
and Evaluation framework; these approaches are 
considered the gold standard for critical appraisal 
of evidence quality.
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for psychosis and schizophrenia have been developed 
to address these aspects, and in accordance with guide-
lines from the National Institute for Health and Care 
Excellence in the UK3 and the Schizophrenia Patient 
Outcomes Research Team in the USA,4 psychological 
treatments are widely regarded as a necessary interven-
tion for schizophrenia.
A broad range of interventions that can be defined 
as ‘psychological’ have been studied in the treatment 
of schizophrenia. These interventions can be provided 
at different stages of the illness and address different 
aspects, like social and cognitive functioning, adherence 
to medication and symptoms of schizophrenia. Table 1 
presents the panorama of existing systematic reviews 
of randomised controlled trials (RCTs) that have been 
conducted on the topic. These reviews have mainly 
included studies comparing the intervention under 
examination with so called no treatment conditions (wait-
ing-list and treatment as usual (TAU)).5 6 Other reviews 
included also active comparisons with other psycholog-
ical treatments.7–9 An attempt to provide information on 
active comparisons was made by Turner and colleagues, 
who performed separate meta-analysis when there were 
at least five eligible RCTs comparing one intervention 
to another psychological intervention.10 However, all 
the available reviews applied pairwise meta-analysis as a 
method, being able to pool results only when a compar-
ison of two treatments was considered in existing studies. 
The comparative efficacy and tolerability of the existing 
interventions have not been checked yet; as a result, it 
is still currently unclear which are the most efficacious, 
the most acceptable and the best tolerable psychological 
treatments for schizophrenia.
To overcome this gap in the current knowledge, a NMA 
would be necessary to consider both direct and indirect 
comparisons, and produce hierarchies of the effects of the 
various psychological treatments in the various efficacy 
and tolerability outcomes. Such hierarchies are essen-
tial for guidelines, which should ideally be able to indi-
cate which treatment is likely to be the best, the second 
best and so on for a given outcome. Only the method of 
NMA can provide such hierarchies by combining all the 
randomised evidence. Our aim is to produce such a NMA 
of all psychological interventions for schizophrenia in 
multiple outcomes. We focus here on the interventions 
primarily aimed at treating positive symptoms in the 
acute phase of the illness.
Objectives
To estimate relative treatment effects and obtain a hier-
archy for the psychological treatments in patients with 
schizophrenia, in terms of:
1. efficacy on positive symptoms.
2. acceptability.
3. other efficacy measures, such as overall symptoms, 
negative symptoms, response, relapse, adherence, de-
pression, quality of life and functioning.
4. tolerability.
MEthOds And AnAlysIs
Criteria for considering studies for this review
Methods for this systematic review have been developed 
according to the Preferred Reporting Items for Systematic 
review and Meta-Analysis Protocols (PRISMA-P) check-
list, and the PRISMA extension statement for reporting 
of systematic reviews incorporating NMA of healthcare 
interventions.11 12 This systematic review and NMA is 
registered in the PROSPERO database; the record in 
PROSPERO will be updated with any amendment made 
to the protocol.
types of studies
We will include all RCTs in which participants with schizo-
phrenia received a psychological intervention as defined 
below (see Types of interventions section). Studies whose 
sequence generation was at high risk of bias (eg, rando-
misation by the date of birth or day of the week) will be 
excluded. We will accept open and blinded RCTs; this 
choice is particularly relevant in trials on psychological 
interventions, in which in best case only the assessor of 
outcome can be blind, but not the therapist. Open RCTs 
will be excluded in a sensitivity analysis. We will include 
both trials in which psychological interventions were 
compared with a control condition and trials in which 
they were compared with another intervention. There 
will be no language restriction in order to avoid the 
problem of ‘language bias’.13 In case we retrieve refer-
ences in languages in which we are not fluent, study 
authors will be contacted to check inclusion criteria and 
eventually ask for study data. As an exception, we will not 
search Chinese databases, since serious concerns have 
been raised on the trustworthiness of Chinese trials found 
in these databases.14 15 Chinese studies found in Western 
databases will be considered for inclusion. In the case 
of cross-over studies, we will use only the first cross-over 
phase in order to avoid the problem of carry-over effects 
which are very likely in schizophrenia and with psycholog-
ical treatments. We will exclude cluster RCTs.
types of participants
Our aim is to collect information on the efficacy of 
psychological treatments on patients with positive symp-
toms. In order to select this population, we operation-
alised the inclusion criteria as follows. We will include 
adults, however defined by study authors, with a diagnosis 
of schizophrenia or related disorders (such as schizo-
phreniform or schizoaffective disorders); there is no clear 
evidence that the latter schizophrenia-like psychoses are 
caused by fundamentally different disease processes or 
require different treatment approaches.16 We will include 
trials irrespective of the diagnostic criteria used. Here we 
will follow the strategy of the Cochrane Schizophrenia 
Group17 to include not only studies that used specific 
diagnostic criteria such as International Classification 
of Diseases, 10th revision or Diagnostic and Statistical 
Manual of Mental Disorders, 5th edition, because these 
criteria are not meticulously used in clinical routine 
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Table 1 Existing reviews about psychological treatments for schizophrenia
Intervention Existing reviews RCT* Comparator
Acceptance and commitment 
therapy
Ongoing Cochrane review42 – TAU, pharmacological intervention and another 
psychosocial intervention
Adherence interventions Gray et al43 6 TAU and didactic health education
Active comparisons (befriending, 
CBT, cognitive remediation, 
psychoeducation, social skills 
training, supportive counselling)
Turner et al10 48 Befriending, CBT, cognitive remediation, psychoeducation, 
social skills training, supportive counselling, family 
intervention, art therapy, body psychotherapy, 
occupational therapy and problem-solving therapy
Art therapy Ruddy and Milnes6 2 Standard care
Assertive community treatment Marshall and Lockwood44 20† TAU, hospital-based rehabilitation and case management
Befriending –
Bibliotherapy –
Body-oriented psychological 
therapy
–
Case management Dieterich et al45 40† Assertive community treatment, assertive outreach model, 
case management model and standard community care
CBT Zimmermann et al (positive 
symptoms)9
15 Waiting-list, TAU or another therapeutic treatment
Jones et al7 20 Active (psychoeducation, family intervention, supportive 
psychotherapy, supportive counselling, cognitive 
remediation) and non-active control treatments (recreation 
and support, social activities, befriending and non-specific 
counselling)
Jauhar et al46 52 Waiting-list, TAU or an intervention designed to control 
for the non-specific effects of psychotherapy (recreation 
and support, group support, befriending, supportive 
counselling/therapy, social activity therapy and goal-
focused supportive contact) or active treatments (cognitive 
remediation and psychoeducation)
Van der Gaag et al 
(individually tailored)47
18 Any control condition was accepted
Hazell et al (low intensity)48 8 TAU and supportive psychotherapy
Kennedy and Xyrichis 
(auditory hallucinations)49
2 Non-specialised therapy (focused on supportive 
interactions and social integration)
Cognitive remediation Cella et al50 45 TAU, active control (eg, computer games) another active 
treatment (eg, CBT)
Dance therapy Ren and Xia51 1 Standard care plus supportive counselling
Family interventions Pitschel-Walz et al52 25 TAU, patient intervention, other family interventions
Pharoah et al53 25 TAU, discussion groups, psychoeducation, supportive 
psychotherapy, psychosocial support
Group psychotherapeutic 
treatments
Orfanos et al54 34 TAU and other groups (active discussion group, support 
group, counselling group, occupational therapy group or 
problem-solving discussion group)
IPT Roder et al55 16 TAU, placebo-attention condition and other active 
treatments
Psychological and psychosocial 
interventions for negative 
symptoms in psychosis
Lutgens et al8 95 TAU and active comparator (including psychoeducation, 
supportive therapy and cognitive remediation)
Metacognitive training Eichner and Berna56 12 TAU, wait-list control, supportive therapy, newspaper 
discussion group, CogPack (=cognitive remediation)
Mindfulness Aust and Bradshaw57 11† Active control intervention (eg, befriending and progressive 
muscle relaxation) and TAU
Music therapy Geretsegger et al58 18 Placebo defined as an alternative therapy designed to 
control for effects of the therapist’s attention; TAU or no 
treatment
Continued
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either. This decision should increase generalisability and 
representativeness.
Studies including participants with other diagnoses 
part of the psychosis spectrum will be included only if 
participants with a diagnosis of schizophrenia, schizo-
phreniform or schizoaffective disorders were >80% of the 
participants considered. We will include studies recruiting 
patients with positive symptoms, either delusions, halluci-
nations or both, or in the phase of acute exacerbation of 
positive symptoms, however defined by inclusion criteria 
of the trial.
We will exclude studies focused on specific subpop-
ulations of patients, such as (A) studies recruiting 
patients in which negative symptoms are predominant, 
according to authors’ definition, (B) studies on patients 
with comorbid psychiatric disorders including substance 
abuse, (C) studies recruiting patients with concomitant 
medical illnesses, (D) trials enrolling stable patients 
(relapse prevention studies), (E) studies on first-episode 
patients and (F) trials on patients who show prodromal 
signs of psychosis (also defined as ‘at risk for psychosis’). 
Among other reasons, we exclude first-episode patients 
because they were found to have significantly higher 
response rates to treatments compared with chronic 
patients.18 19
types of interventions
Any psychological intervention that occurs through inter-
action between therapist and patient, either face-to-face 
individually or in group, with the primary aim to reduce 
positive symptoms. Interventions with an explicit primary 
aim different from positive symptoms (eg, functioning, 
cognition, adherence to medication and knowledge of 
the illness) will be excluded. The identified treatments 
will be classified after identification of eligible studies. 
Psychological treatments will be compared with each 
other and to any non-pharmacological control condition 
considered in the included studies. Comparators will 
include the so called ‘treatment as usual’, waiting-list and 
inactive treatments. The effect of ‘non-active’ compara-
tors will be analysed in a sensitivity analysis.20 Patients also 
receiving treatment as usual, including pharmacological 
interventions, will be included. If psychological treat-
ments that we do not include among the interventions 
(eg, psychoeducation and supportive therapy) are used as 
control condition in the studies, they will be included as 
nodes in order to strengthen the network, but will not be 
part of our decision set.
Outcome measures
Outcomes will be measured at study endpoint, as defined 
in each study.
Primary outcome
Change in positive symptoms of schizophrenia, examined 
accordingly to the respective subscale of the Positive and 
Negative Syndrome Scale (PANSS), the Brief Psychiatric 
Rating Scale (BPRS) or the Scales for Assessment of Posi-
tive Symptoms or any other published scale.
As not all studies will have used the same scale, we 
will extract data according to the following hierarchy: 
mean change of the PANSS positive symptoms subscale 
from baseline to endpoint, if not available mean change 
of the BPRS positive symptoms subscale or if again not 
available the mean values at endpoint of the PANSS/
BPRS positive symptoms subscale. The results of other 
rating scales will only be used if the instrument has been 
published in a peer-reviewed journal, because it has been 
shown that non-validated schizophrenia scales exaggerate 
differences.21
secondary outcomes
Given the focus on treatments for positive symptoms, 
the results of this review will be informative for the treat-
ment of positive symptoms. They will also describe how 
these interventions can have an effect on a number of 
other outcomes. With this aim, the following secondary 
outcomes will be assessed:
Intervention Existing reviews RCT* Comparator
Psychodynamic therapy Malmberg and Fenton59 4 Reality adaptive, supportive psychotherapy, hospital 
comparison, ataraxic drugs, electro convulsive therapy, 
Milieu therapy and individual versus group
Psychoeducation Pekkala and Merinder60 10 TAU, supportive psychotherapy, behavioural intervention 
and leisure-time group
Social skills training Almerie et al61 13 TAU, structured activities, discussion group, interaction 
group, and no treatment control
Supportive therapy Buckley et al62 24 Standard care, any other treatment (biological, 
psychological or social) such as medication, problem-
solving therapy, psychoeducation, social skills training, 
CBT, family therapy or psychodynamic psychotherapy
Systemic therapy Pinquart et al5 7 No treatment
*Number of RCTs on patients with schizophrenia .
†RCTs about patients with severe mental illness including schizophrenia.
CBT, cognitive–behavioural therapy; IPT, integrated psychological therapy; RCT, randomised controlled trial; TAU, treatment as usual.
Table 1 Continued 
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1. Acceptability, defined as the percentage of patients 
leaving the study early (dropout) for any reason. All-
cause discontinuation due to any reason combines 
efficacy, tolerability and other factors, and can there-
fore be considered as a measure of ‘acceptability of 
treatment’17 or of overall ‘effectiveness’.
2. Change in overall symptoms, measured by rating 
scales such as the PANSS or the BPRS, or any other 
published scale (eg, the Manchester Scale) for the 
assessment of overall schizophrenic symptomatology. 
The results of other rating scales will only be used if 
the instrument has been published in a peer-reviewed 
journal.
3. Change in negative symptoms, measured by the re-
spective subscale of the PANSS, or the ‘Scales for 
Assessment of Negative Symptoms’ or any other pub-
lished scale.
4. Response, measured by the percentage of responders 
defined by reduction on the PANSS, BPRS or Clinical 
Global Impression (CGI) scores, accepting the crite-
ria used by study authors.
5. Percentage of patients with relapse, by definitions 
operationalised by rating scales, and, if not available, 
number of rehospitalisations due to psychopatholo-
gy. We will not include data from studies that used 
non-operationalised relapse criteria (eg, clinical 
judgement).
6. Adherence, measured by any published rating 
scale (eg, ‘Adherence Therapy Patients Satisfaction 
Questionnaire’ and ‘Adherence Rating Scale’).
7. Depression, measured by the Calgary Depression 
Scale for Schizophrenia, the Hamilton Depression 
Rating Scale, the Montgomery Asberg Depression 
Scale or other published symptom scales.
8. Quality of life, measured by any published rating 
scale (eg, ‘Heinrichs quality of life scale’, Quality of 
Life Scale.
9. Functioning, measured by rating scales such as the 
Global Assessment of Functioning or the Psychosocial 
Performance Scale, or any other published rating 
scale.
10. Tolerability, measured as the percentage of patients 
experiencing adverse events. Adverse events associ-
ated with psychological treatments are not covered 
as comprehensively as in trials on pharmacological 
treatments.22 However, there is a raising awareness of 
the importance of considering possible harms asso-
ciated with psychological interventions.23 Therefore 
we will collect any available information in clinical 
studies about this outcome, using a classification pro-
posed by Linden and colleagues23 : (A) emergence 
of new symptoms; (B) deterioration of existing symp-
toms; (C) lack of improvement or deterioration of 
illness; (D) prolongation of treatment; (E) patient’s 
non-compliance; (F) strains in the patient–therapist 
relationship; (G) very good patient–therapist rela-
tionship, therapy dependency; (H) strains or chang-
es in family relations; (I) strains or changes in work 
relations; (J) any change in the life circumstances of 
the patient; (K) stigmatisation. Suicide attempts and 
any other possible adverse event related to psycholog-
ical treatment will also be considered.
11. Mortality. Psychosocial treatments may actually re-
duce or, by contrast, increase overall mortality, in par-
ticular connected to suicidality. To test this, we will 
examine this outcome in terms of (A) death for any 
reason, (B) death due to natural causes and (C) due 
to suicide.
search strategy
Electronic searches
The following sources will be searched without restrictions 
for language or publication period: Embase, MEDLINE, 
PsycINFO and PubMed. The search terms that will be 
used for PubMed are provided as online supplementary 
material. We will also search the following international 
databases:
1. WHO International Clinical Trials Registry Platform,
2. BIOSIS,
3. Cochrane Collaboration Controlled Trials Register,
4.  ClinicalTrials. gov.
Reference lists and other sources
References of all selected studies will be inspected for other 
published reports and citations of unpublished studies. We 
will also inspect previous reviews conducted on psycholog-
ical treatments for schizophrenia to check if some studies 
meet our inclusion criteria as well. In addition, we will 
contact the first author of each included study published in 
the last 30 years for missing information about their studies.
Identification and selection of studies
Studies identified through electronic and manual 
searches will be listed with citation, titles and abstracts, 
in Citavi; duplicates will be excluded. The eligibility for 
inclusion process will be conducted in two separate stages:
1. Two authors will independently inspect title and 
abstracts identified in the literature searches and 
exclude those not pertinent. Disagreement will be re-
solved by discussion and where doubt still remains, we 
will acquire the full article for further inspection and 
the article will proceed to the next stage.
2. Once the full articles are obtained, two review-
ers will independently assess them for eligibility. 
Disagreements will be resolved by discussion and, if 
needed, a third senior author will be involved. When 
required, further information will be obtained from 
study authors.
data extraction
Two authors will independently extract data from all 
selected trials. When disagreement arises we will resolve 
it by discussion and, if needed, involving a third senior 
author. Where this is not sufficient we will contact the 
study authors.
The following data will be collected from each included 
study:
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 ► Study citation, year(s) of study, registration number to 
trials registries, year of publication, location, setting, 
number of centres, sample size, diagnostic criteria and 
funding/sponsor (industry or academic).
 ► Methodology, including study design (type of RCT), 
number of arms and risk of bias (see Risk of bias 
assessment section).
 ► Characteristics of study participants, including 
gender, age, details on diagnosis, number randomised 
to each arm, sociodemographic characteristics, 
whether psychological treatments naive at baseline 
or with previous experience with the experimental 
intervention).
 ► Characteristics of intervention, including number 
and frequency of sessions, therapy setting, expertise 
of therapist and researcher allegiance at study arm 
level.
 ► Outcome measures, including information on 
whether an intention-to-treat approach has been used 
and how it was defined.
The two reviewers will independently input data into 
an Access database, especially created for this study. The 
software will automatically detect any inconsistencies and 
they will be resolved by discussion.
Measurement of treatment effect
Relative treatment effects
 ► Continuous outcomes: for continuous outcomes we 
will use the standardised mean difference (SMD), 
because we expect that the studies use different rating 
scales of overall schizophrenia symptomatology.
 ► Dichotomous outcomes: the effect size for dichoto-
mous outcomes will be the risk ratio (RR) and its 95% 
CIs.
Relative treatment ranking
We will estimate the probability for each intervention 
to be ranked at each possible place, given the relative 
effect sizes as estimated in NMA. As described in Salanti 
et al,24 we will obtain a hierarchy of the competing inter-
ventions using the surface under the cumulative ranking 
curve (SUCRA) and mean ranks. SUCRA values will be 
expressed as percentage, showing the relative probability 
of an intervention to be among the best options.
Dealing with missing outcome data and missing statistics
For continuous outcomes we will extract data for all 
randomised patients, if possible, and we will give prefer-
ence to data based on mixed-effect models of repeated 
measurements of multiple imputations over last-observa-
tion-carried-forward data.
We will use published SDs, where available. When 
SEs instead of SDs are presented, the former will be 
converted to SDs.25 If both are missing, we will estimate 
SDs from P values or CIs, as described in Section 7.7.3 
of the Cochrane Handbook for Systematic Reviews.26 If 
none of these options are viable, we will contact the orig-
inal authors. When no information can be obtained we 
will derive SDs from those of the other studies using a 
validated imputation technique.25
For dichotomous outcomes, everyone allocated to the 
intervention will be counted whether they completed the 
follow-up or not. If the authors applied such a strategy, 
we will use their results. If the original authors presented 
only the results of the per-protocol or completer popu-
lation, we will assume that those participants lost to 
follow-up would not have changed in a given outcome. In 
terms of efficacy, this means that they would be conserva-
tively considered to have not responded to treatment or 
control. In terms of tolerability, it would mean that partic-
ipants would not have developed a side-effect.
risk of bias assessment
Risk of bias will be assessed for each included study using 
the Cochrane Collaboration ‘risk of bias’ tool.26 27 The 
following domains will be considered:
1. Sequence generation: was the allocation sequence ad-
equately generated?
2. Allocation concealment: was allocation adequately 
concealed?
3. Blinding of participants: was knowledge of the allocat-
ed treatment adequately prevented during the study? 
Given the peculiarity of the included studies, in which 
the therapist cannot be blind, we will consider under 
this item only if a way was found to keep patients un-
aware of the treatment they were receiving (even if we 
expect this will not be likely).
4. Blinding of outcome assessors: were outcomes evalu-
ated by blind raters? Were adequate measures taken 
to prevent them from discovering treatment alloca-
tion during the study?
5. Incomplete outcome data: were incomplete outcome 
data adequately addressed?
6. Selective reporting: are reports of the study free from 
suggestion of selective outcome reporting?
7. Researcher’s allegiance: do the researchers involved 
have a vested interest for the psychological treatment 
under investigation? We will additionally consider 
this point as possible source of bias, since it has been 
claimed to be relevant in trials on psychological inter-
ventions.28–30 An evaluation of high risk of bias will be 
given, for example, when the authors are founders of 
the therapy or have written a manual for that therapy.
A description of what was reported about the same 
domains in each study will be provided, and a judgement 
on the risk of bias will be made for each one of them, 
based on the following three categories: ‘high risk of 
bias’, ‘low risk of bias’ and ‘unclear risk of bias’ where 
information are not sufficient to make a judgement. Two 
independent review authors will assess the risk of bias in 
the selected studies. Any disagreement will be resolved 
through discussion. Where necessary, the authors of the 
studies will be contacted for further information. Studies 
will be classified as having low risk of bias if none of the 
domains above were rated as high risk of bias and three 
or less were rated as unclear risk; moderate if one was 
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rated as high risk of bias or none was rated as high risk 
of bias, but four or more were rated as unclear risk and 
all other cases will be assumed to pertain to high risk of 
bias.31 We will not include studies in the data analyses 
whose sequence generation was at high risk of bias (eg, 
randomisation by the date of birth or day of the week). 
Effects of high risk of bias in the other domains will be 
analysed by sensitivity analyses.
data analysis
Characteristics of the included studies
We will produce descriptive statistics and study popula-
tion characteristics across all eligible trials, describing the 
types of comparisons and other clinical or methodolog-
ical variables, such as age, duration of illness, comedica-
tion, country, duration of study and number of sessions.
Two-step procedure
In a first step, we will perform series of conventional pair-
wise meta-analyses by combining studies that compared 
the same interventions, including the comparison 
between active treatments and the different control 
arms. In subgroups with very few RCTs available or if the 
requirements of NMA are not met, it can be that NMA 
will not be appropriate and, in this case, conventional 
pairwise meta-analysis will be the most straightforward 
approach. As heterogeneity is likely, a random-effects 
model will be used. In a second step, we will then perform 
a NMA within a frequentist framework.
Assessment of heterogeneity
The heterogeneity (variability in relative treatment effects 
within the same treatment comparison) will be measured 
with the tau-squared (the variance of the random-effects 
distribution). The heterogeneity variance will be assumed 
common across the various treatment comparisons 
(grouped by comparison type) and the empirical distri-
butions will be used to characterise the amount of hetero-
geneity as low, moderate or high using the first and third 
quantiles.32–34 Potential reasons for heterogeneity will be 
explored by subgroup analysis (see below).
Assessment of the transitivity assumption
Joint analysis of treatments can be misleading if the 
network is substantially intransitive. We assume that 
patients who fulfil the inclusion criteria outlined in 
criteria for considering studies for this review section are 
equally likely to be randomised to any of the interven-
tions that we plan to compare. We will need to investigate 
the distribution of clinical and methodological variables 
that can act as effect modifiers across treatment compar-
isons.35 We have maximised the chances of transitivity in 
our network with regard to clinical variables by limiting 
our samples to participants with schizophrenia and 
excluding specific subgroups like first-episode patients or 
patients with prevalent negative symptoms. Other clinical 
or methodological variables that may influence the effi-
cacy of psychological interventions include administra-
tion mode and frequency of the treatment (like number 
of sessions and experience of the therapist), baseline 
severity (see ‘Investigation of heterogeneity and inconsis-
tency’) and blinding, which will also be assessed in sensi-
tivity analyses. We will investigate if these variables are 
similarly distributed across studies grouped by compar-
ison. The comparability of studies comparing the inter-
vention with treatment as usual or waiting-list conditions 
with those that provide head-to-head evidence will be 
examined carefully.
Network meta-analysis
NMA combines direct and indirect evidence for all rela-
tive treatment effects and can therefore provide esti-
mates with maximum power and increased precision.36 
If the collected studies appear to be sufficiently similar 
with respect to the distribution of effect modifiers (refer 
the Assessment of transitivity assumption section), we will 
conduct a random-effects NMA to synthesise all evidence 
for each outcome, and obtain a comprehensive ranking 
of all treatments. We will assume a single heterogeneity 
parameter for each network. We will present the summary 
SMDs or RRs for all pairwise comparisons in a league 
table. We will also estimate the prediction intervals to 
assess how much the common heterogeneity affects the 
relative effect with respect to the extra uncertainty antic-
ipated in a future study. To rank the various treatments 
for each outcome, we will use the SUCRA and the mean 
ranks.
Assessment of inconsistency
The strategical and conceptual evaluation of transitivity 
will be supplemented with a statistical evaluation of 
consistency, the agreement between direct and indirect 
evidence. We will employ local as well as global methods 
to evaluate consistency.37 Local methods detect ‘hot spots’ 
of inconsistency, evidence loops that are inconsistent 
or comparisons for which direct and indirect evidence 
disagree. We will employ a method that separates direct 
evidence from indirect evidence provided by the entire 
network and then evaluate the agreement of these two 
pieces of evidence.38 We will also evaluate consistency in 
the entire network by calculating the design-by-treatment 
interaction test and I-squared for network heterogeneity, 
inconsistency, and for both.39 Tests for inconsistency 
are known to have low power, and empirical evidence 
has suggested that 10% of evidence loops published in 
the medical literature are expected to be inconsistent.40 
Therefore, interpretation of the statistical inference 
about inconsistency will be carried out with caution and 
possible sources of inconsistency will be explored even in 
the absence of evidence for inconsistency.
Investigation of heterogeneity and inconsistency
We expect small amounts of heterogeneity and inconsis-
tency to be present given the variety of study settings we 
plan to include. The following potential effect modifiers 
of the primary outcome will be explored by subgroup 
analyses:
group.bmj.com on March 27, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
8 Bighelli I, et al. BMJ Open 2018;8:e019280. doi:10.1136/bmjopen-2017-019280
Open Access 
A. Number of sessions,
B. Study duration,
C. Setting: individual versus group,
D. Expertise of the therapist,
E. Baseline severity (PANSS or BPRS score at baseline),
F. Different types of patients, with a different clinical 
outline concerning symptoms (if identified).
Sensitivity analyses
We will explore the following sensitivity analyses by excluding:
A. Studies in which the outcome assessor was not blind 
(open studies);
B. Studies that presented only completer analyses;
C. Studies characterised as pertaining to high risk of bias;
D. Studies with high risk of bias in researchers’ alle-
giance;
E. Studies focused on treatment resistant patients (study 
defined);
F. Studies with a non-active comparison group.
Publication bias
We will first examine funnel plots of pairwise NMAs 
if there are 10 or more studies included. We will also 
explore the association between study size and effect size 
with a comparison-adjusted funnel plot that has been 
adapted to NMA.41
Evaluating the quality of the evidence
The quality of evidence contributing to each network esti-
mate will be evaluated using an adaptation of the Grading 
of Recommendations Assessment, Development and 
Evaluation framework specifically developed for NMA.37 
We will characterise the credibility of a body of evidence 
based on the study limitations, imprecision, heteroge-
neity/inconsistency, indirectness and publication bias.
Statistical software
The analysis and presentation of results will be performed 
using the Stata packages network and network_graphs, 
and the R package netmeta.
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